Markets:

Overview

News

Currencies

International

Treasuries

Sonnet BioTherapeutics Holdings, Inc. - Common Stock (NQ:SONN)

1.260 UNCHANGED

Last Price Updated: 4:00 PM EST, Dec 2, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sonnet BioTherapeutics Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain

June 13, 2024

From Sonnet BioTherapeutics Holdings, Inc.

Via GlobeNewswire

Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting

May 28, 2024

From Sonnet BioTherapeutics Holdings, Inc.

Via GlobeNewswire

Sonnet BioTherapeutics Provides Fiscal Year 2023 Business Overview

October 31, 2023

Via ACCESSWIRE

Sonnet BioTherapeutics Announces Review of Strategic Alternatives

May 22, 2024

Via ACCESSWIRE

Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target

May 20, 2024

Via ACCESSWIRE

SONN Stock Earnings: Sonnet BioTherapeutics Misses EPS for Q2 2024 ↗

May 15, 2024

SONN stock results show that Sonnet BioTherapeutics missed analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update

May 14, 2024

Via ACCESSWIRE

Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference

May 06, 2024

Via ACCESSWIRE

Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting

March 19, 2024

Via ACCESSWIRE

Sonnet BioTherapeutics Announces Early Safety Data from the Company’s Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study’s Initial Pre-Specified Objective

March 11, 2024

Via ACCESSWIRE

Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers

February 29, 2024

Via ACCESSWIRE

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

February 14, 2024

Via Benzinga

Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update

February 14, 2024

Via ACCESSWIRE

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

February 13, 2024

Via Benzinga

Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy

December 21, 2023

Via ACCESSWIRE

Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update

December 14, 2023

Via ACCESSWIRE

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

November 28, 2023

Via Benzinga

What's Happening With Sonnet BioTherapeutics (SONN) Shares? ↗

October 26, 2023

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares are trading lower by 8.5% to $1.18 Thursday morning on downward momentum.

Via Benzinga

Dow Falls Over 100 Points; Alphabet Shares Tumble After Q3 Results ↗

October 25, 2023

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 100 points on Wednesday. The Dow traded down 0.35% to 33,025.71 while the NASDAQ fell 2.45% to 12,817.76....

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

October 25, 2023

Via Benzinga

Why Owens Corning Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

October 25, 2023

Gainers Abri SPAC I, Inc. (NASDAQ: ASPA) shares climbed 127.1% to $28.39. Abri's stockholders approved its proposed business combination with DLQ.

Via Benzinga

Crude Oil Edges Higher; Thermo Fisher Scientific Cuts FY23 Forecast ↗

October 25, 2023

U.S. stocks traded mostly lower midway through trading, with the Nasdaq Composite falling more than 150 points on Wednesday. The Dow traded up 0.20% to 33,206.51 while the NASDAQ fell 1.76% to...

Via Benzinga

Topics Stocks

Why Sonnet BioTherapeutics (SONN) Stock Is Getting Hammered ↗

October 25, 2023

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares are trading lower by 27.6% to $1.31 Wednesday morning after the company announced the pricing of a public offering involving 2,843,750 shares...

Via Benzinga

EVGO Stock Slips as TD Cowen Downgrades EVgo ↗

October 25, 2023

EVgo stock is taking a beating on Wednesday as investors in the EV charging company deal with a downgrade and price cut.

Via InvestorPlace

Nasdaq Down 1.5%; Microsoft Posts Upbeat Results ↗

October 25, 2023

U.S. stocks traded lower this morning, with the Nasdaq Composite falling 1.5% on Wednesday. Following the market opening Wednesday, the Dow traded down 0.26% to 33,053.68 while the NASDAQ fell 1.50% to...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

October 25, 2023

Via Benzinga

Why Is InMed Pharmaceuticals (INM) Stock Down 25% Today? ↗

October 25, 2023

InMed Pharmaceuticals stock is falling on Wednesday after shares of INM underwent a massive rally on Tuesday alongside study results.

Via InvestorPlace

Why Is Sonnet BioTherapeutics (SONN) Stock Down 33% Today? ↗

October 25, 2023

Sonnet BioTherapeutics stock is dropping on Wednesday after the company revealed the pricing of a public offering for SONN shares.

Via InvestorPlace

Why Microsoft Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket ↗

October 25, 2023

Gainers ReShape Lifesciences Inc. (NASDAQ: RSLS) shares surged 62.8% to $0.3348 in pre-market trading after gaining over 6% on Tuesday. ReShape Lifesciences recently announced pricing of $3.0 million...

Via Benzinga

Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offering

October 25, 2023

Via ACCESSWIRE

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sonnet BioTherapeutics Holdings, Inc. - Common Stock (NQ:SONN)

All News about Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today